John J. Cush

Comorbidity burden, uveitis, & psoriasis independently assoc w/ greater spinal radiographic progression in AS. Study3,441 pts (75% male; 84% B27+). Progression greater w/ 2+ comorbidities & uveitis, & PSO https://t.co/7Zh5SlMKc0 https://t.co/lmonP5YrcV Dr. John Cush @RheumNow( View Tweet ) Apr 26, 2026 Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.

Introduction The discovery and introduction of corticosteroid therapy by Philip Hench in the late 1940s and early 1950s was a seminal advance in the treatment of inflammatory diseases, including rheumatoid arthritis (RA). Prior to the introduction of steroids, RA therapy was dominated by poorly effective and toxic therapies (aspirin and gold salts). The glucocorticoid compounds became well known for their impressive and rapid clinical efficacy in a variety of inflammatory clinical disorders.

A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19. Both MAbs are neutralizing antibodies against SARS